Investors and Media
Press Releases
October 23, 2025
Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025
October 17, 2025
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 23, 2025
FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility
September 12, 2025
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 15, 2025
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 14, 2025
Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment
August 6, 2025
Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
July 21, 2025
